Imiquimod 3.75% for field‐directed therapy of actinic keratosis: results of a prospective case‐series study in Greece

BACKGROUND: Imiquimod 3.75% is a field‐directed treatment for actinic keratosis that can detect and treat clinical and subclinical lesions across an entire sun‐exposed field. The detection of subclinical lesions is evidenced by an increase in lesions to the maximum lesion count during treatment (L (...

Descripción completa

Detalles Bibliográficos
Autores principales: Befon, Angeliki, Tzanetakou, Vassiliki, Panagiotopoulos, Antonios, Chasapi, Vasiliki, Antoniou, Christina, Stratigos, Alexander J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850341/
https://www.ncbi.nlm.nih.gov/pubmed/30779341
http://dx.doi.org/10.1111/ijd.14397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850341/
https://www.ncbi.nlm.nih.gov/pubmed/30779341
http://dx.doi.org/10.1111/ijd.14397

Ejemplares similares